US EditionPublished • loading... • Updated
Model Medicines Demonstrates First Single-Agent Antiviral Active Against Both Hepatitis C & Hepatitis B
Summary by Stemwell Science News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Model Medicines Demonstrates First Single-Agent Antiviral Active Against Both Hepatitis C & Hepatitis B
Model Medicines announced preclinical data demonstrating that MDL-001 has potent antiviral activity against both hepatitis C virus (HCV) and hepatitis B virus (HBV). These results establish preclinical proof of concept for a single non-nucleoside agent targeting HCV/HBV co-infection. [Model Medicines] Press Release
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
